Projekt · Dnr 2019-01498 · Källa: Vinnova

UTVECKLING AV BIOLOGISKT LÄKEMEDEL FÖR ORALA INDIKATIONERNA PERIODONTIT OCH PERI-IMPLANTIT

Koordinator
Omnio AB
Projekttid
2019-06-01 till 2021-10-31 (avslutat)
Beviljat bidrag
3 000 000 SEK
Diarienummer
2019-01498

Beskrivning

The aim was to develop two plasminogen-based drug candidates for treatment of periodontitis and peri-implantitis. The goal was to have an injectable and a paste/ointment/granule for topical application. The work with injectable plasminogen for treatment of periodontitis has progressed well using our mouse models. For topical treatment we have identified that a carrier substance (Lyostypt) which is already used in oral indications can adsorb plasminogen and thus be used as a carrier material. The work on peri-implantitis was technically very difficult but is still on-going. We have discussed with experts to evaluate and select a proper treatment strategy as well as the regulatory requirements. Since our industrial partner sold the plasminogen production capacity we decided to produce recombinant GMP-plasminogen on our own. Funding for this was obtained through a private placement and a CMO has been selected. A letter of intent for the financing of the project through clinical trials have been obtained. The periodontitis and peri-implantitis models in rodents have been optimized. Formulation studies for topical formulations have been performed.

Öppna hos Vinnova

Hittar Vinnova inte sidan? Sök på diarienumret hos Vinnova.

Liknande

  1. Development and clinical microdose study of an albumin-binding PET imaging agent for blood flow measurement

    Affibody AB · 2010-11-08 · 5 000 000 SEK · Projekt

    <p>The goal of the project was to develop and produce a novel radiotracer for imaging of blood flow/permeability in tumors and to investigate its suitability in first clinical trials. Peptide synthesis yielded functional and stable ABY-028. In vivo studies with [68Ga]ABY-028 proved the suitability f…

  2. E!11019, OptiFemVac, Abera Bioscience AB

    Abera Bioscience AB · 2017-04-01 · 2 351 980 SEK · Projekt

    The purpose was to engineer bacterial outer membrane vesicles (OMVs) into a versatile and modular platform for recombinant vaccine development. Technology was developped to couple high amounts of antigenic proteins to OMV particles and vaccine candidates against either Zika virus or Humano papiloma …

  3. AI-baserad journalscreening för patientsäker magnetkameraundersökning

    Region Östergötland · 2020-04-15 · 497 925 SEK · Projekt

    The purpose of this project was to build an AI model for automatic identification of “implant terms” in medical records. The need of an automatic identification of implant terms spurs from safety reasons because patients who have an implant may be at risk if they undergo Magnetic Resonance Imaging (…

  4. E!11481, E-OxidoCurin, HDXperts AB

    HDxperts AB · 2017-10-01 · 4 888 259 SEK · Projekt

    All the goals of the project were fulfilled. 1) A new water-soluble lead compound LCTA2940 was synthesized. 2) The TrxR1 target was validated, and the mechanism of interaction and ROS dependent action was elucidated. 3) Using proteomics, we identified additional targets. 4) In vivo LCTA2940 effectiv…

  5. Oxynitridbiokeramer för säker och långsiktig virusinaktivering

    Uppsala universitet · 2020-10-01 · 940 986 SEK · Projekt

    The aiming nitride powders were oxidised, characterised and their antiviral properties were tested against copper, an established antiviral agent. The results indicated that oxidised nitride ceramics were highly effective in binding and inactivating SARS-CoV-2, adenovirus, H1N1, and Norovirus after …